Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA(2017)
Abstract
New treatments with novel mechanisms of action are needed for patients with relapsed/refractory (R/R) DLBCL and FL. These tumor cells may depend on the histone methyltransferase EZH2 to perpetuate a less-differentiated state, and activating mutations may be oncogenic drivers. Tazemetostat, a potent, selective EZH2 inhibitor, shows antitumor activity in preclinical models and a phase 1 study in patients (pts) with mutated or wild-type (wt) EZH2 tumors.
MoreTranslated text
Key words
ezh2 inhibitor,tazemetostat,b-cell,non-hodgkin
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined